X

Trial Profile

A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etavopivat (Primary)
Indications Alpha-thalassaemia; Beta-thalassaemia; Sickle cell anaemia
Focus Therapeutic Use
Acronyms 4202-HEM-201; Gladiolus
Sponsors FORMA Therapeutics; Novo Nordisk

Most Recent Events

10 Dec 2023 Planned End Date changed from 31 Jul 2025 to 1 Dec 2025.
10 Dec 2023 Planned primary completion date changed from 30 Mar 2025 to 3 Nov 2025.
05 Aug 2022 According to a FORMA Therapeutics media release, results are expected by year-end.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com